Frontotemporal Dementia

🔍 Three Things You Likely Didn’t Know About Frontotemporal Dementia

1. The average FTD patient sees three or more doctors and waits 3-4 years for the right diagnosis. Because FTD presents with personality changes and loss of empathy — not memory loss — it is frequently misdiagnosed as depression, bipolar disorder, or a personality disorder. During those years, inappropriate treatments are tried and family relationships can deteriorate as a result of blaming the patient for becoming “inappropriate.”

2. FTD typically strikes between ages 45 and 65 — while people are still working and raising children. Unlike Alzheimer’s, which usually appears after 65, FTD hits during the most demanding years of life. The collision between a neurodegenerative diagnosis and the demands of mid-life creates a crisis that families and the healthcare system are typically poorly equipped to address.

3. A person with FTD can pass a cognitive test, especially early on, while their spouse feels like they’re living with a stranger. Behavioral variant FTD selectively erodes empathy, social awareness, and emotional connection — while memory and other cognitive abilities remain relatively intact (Rascovsky et al., 2011). Standard cognitive tests often miss it entirely, which is why families’ concerns are sometimes dismissed.

---

📋 Overview

Frontotemporal dementia (FTD) is a group of neurodegenerative disorders caused by progressive atrophy of the frontal and temporal lobes of the brain — regions that govern personality, social behavior, decision-making, language, and emotional regulation. Unlike Alzheimer’s disease, which characteristically begins with memory impairment, FTD most often presents with dramatic changes in who a person is — how they behave, how they relate to others, and how they communicate.

FTD accounts for an estimated 10–20% of all dementia cases and is one of the most common causes of dementia before age 65. It has a strong genetic component: approximately 30–50% of cases have a family history of dementia or a related neurological condition.

Unlike Alzheimer’s, FTD is associated with several different underlying proteins — most commonly tau or TDP-43. This means FTD is not one disease but a family of related diseases unified by where they strike in the brain: the frontal and temporal lobes.

---

🔀 Subtypes and Presentations

FTD is classified into three major clinical syndromes, each with a distinctive presentation:

• Behavioral variant FTD (bvFTD) — the most common subtype, accounting for roughly half of all FTD cases. bvFTD is characterized by progressive changes in personality, social conduct, and behavior. Core features tend to emerge as a progressive and uncharacteristic change in personality and social conduct:

  • Disinhibition — socially inappropriate behavior, loss of manners, impulsive actions, tactless comments
  • Apathy and inertia — profound loss of motivation and initiative
  • Loss of empathy and emotional blunting — diminished responsiveness to others’ feelings, reduced warmth
  • Compulsive and ritualistic behaviors — repetitive movements, rigid routines, hoarding, clock-watching
  • Dietary changes — often a striking shift toward sweet foods, carbohydrate craving, overeating, or food fads
  • Executive dysfunction — impaired judgment, poor planning, difficulty with abstract reasoning

  Crucially, memory and visuospatial function are often relatively preserved early in the disease — which is why standard cognitive screening tests may be normal even when the family is reporting at times unexplainable behavioral changes.

• Semantic variant primary progressive aphasia (svPPA) — a language-dominant presentation characterized by progressive loss of word meaning and object knowledge. Patients may speak fluently but use vague, empty speech because they can no longer access the meanings of specific words. They may fail to recognize familiar objects or people by name while retaining the ability to use them functionally.

• Nonfluent/agrammatic variant primary progressive aphasia (nfvPPA) — characterized by effortful, halting speech with grammatical errors, sound distortions, and difficulty forming sentences, despite relatively preserved word comprehension in the early stages. Patients often become increasingly frustrated as they struggle to express thoughts they can still think clearly.

Some patients present with overlap syndromes, and the clinical picture may evolve over time — for example, a patient who presents initially with language difficulties may gradually develop behavioral features as the disease spreads.

---

🩺 Diagnosis

The diagnosis of FTD requires clinical expertise. Key diagnostic elements include:

• Comprehensive behavioral and psychiatric history — ideally gathered from both the patient and a reliable informant. In bvFTD, patients often lack insight into their behavioral changes and may deny any problem. The informant’s account is frequently the most diagnostically valuable source of information. The clinician benefits from probing for disinhibition, apathy, loss of empathy, compulsive behaviors, and dietary changes — features that are not captured by standard cognitive screening.
• Cognitive and neuropsychological testing — in bvFTD, executive function tests (set-shifting, planning, abstraction) may be impaired while memory and visuospatial scores are relatively spared. In the PPA variants, language-specific assessments are essential. A normal score on the MMSE or MoCA does not rule out FTD — particularly in the earlier stages — and should not be used as the sole basis for dismissing a family’s concerns.
• Neuroimaging — structural MRI may reveal characteristic frontal and/or temporal lobe atrophy, often asymmetric. FDG-PET can demonstrate frontal and temporal hypometabolism even before structural changes are apparent. These imaging findings, when present, can be powerfully confirmatory.
• Genetic testing — can be helpful and indicated when there is a family history of dementia, motor neuron disease, or psychiatric illness with a pattern suggestive of autosomal dominant inheritance.
• Differentiation from psychiatric disorders — this is the diagnostic challenge at the heart of FTD. A middle-aged patient presenting with apathy, personality change, disinhibited behavior, or compulsive rituals may not receive a diagnosis for years before the neurodegenerative nature of the condition is recognized. Key red flags for FTD rather than a primary psychiatric disorder include: onset after age 40 with no prior psychiatric history, progressive worsening despite treatment, loss of empathy that seems neurological rather than characterological, sweet food craving and dietary changes, and the emergence of language difficulties.

---

💊 Treatment Approach

There are currently no disease-modifying treatments for FTD, but this does not mean there is nothing to be done. Psychiatric symptom management, behavioral strategies, caregiver education, and advanced planning are essential components of care that can meaningfully improve quality of life for both patients and families.

Psychotherapy and Behavioral Approaches

In FTD, psychotherapy directed at the patient becomes progressively less feasible as insight and social cognition decline. However, caregiver-focused education, support and even therapy can be tremendously helpful for the family unit in which the patient exists. Acceptance-based and compassion-focused approaches are particularly relevant for FTD caregivers, who face a unique constellation of stressors: their loved one may be physically healthy and cognitively intact enough to resist care, yet profoundly impaired in judgment, empathy, and social behavior, and even unrecognizable to them. Compassion-Focused Therapy (CFT) can help caregivers manage the grief, anger, and guilt that arise when a loved one loses the capacity for empathy.

Structured behavioral management strategies provide practical tools: establishing predictable routines, reducing environmental triggers, and redirecting rather than confronting.

Medication and Neuromodulation

The pharmacological approach to FTD is primarily symptom-targeted. Serotonergic agents may help manage disinhibition, compulsive behaviors, agitation, and the repetitive motor behaviors common in bvFTD. The rationale is grounded in the observation that serotonergic circuits are significantly affected in FTD, particularly in the orbitofrontal and anterior temporal regions.

For agitation and aggression, medications must be chosen carefully. Dopaminergic antagonists carry significant risks in FTD — including extrapyramidal side effects and metabolic complications — and should be used only when non-pharmacological strategies have been insufficient and the behavioral symptoms pose a safety risk.

Apathy — often the most functionally impairing symptom in bvFTD — is among the most difficult symptoms to treat pharmacologically. Agents that modulate dopaminergic and noradrenergic tone may be considered, though response is variable and evidence remains limited.

For the PPA variants, speech-language therapy is the primary intervention. While pharmacotherapy has not shown consistent benefit for the core language deficits, managing the frustration, depression, and anxiety that accompany progressive language loss is a meaningful component of psychiatric care.

Neuromodulation approaches, including TMS and tDCS, are being investigated for behavioral symptoms of FTD, though this remains an area of early research rather than established practice.

Integrative and Lifestyle Approaches

Structured physical exercise, social engagement, and cognitive activities adapted to the patient’s abilities may help maintain function and well-being. Targeted nutritional management can address the dietary dysregulation common in bvFTD — which, if unchecked, can lead to significant weight gain, metabolic complications, and dental problems. Emerging research on neuroinflammation, gut-brain interactions, and neuroprotective strategies in FTD is at an early stage but offers intriguing avenues for individualized complementary approaches. The specifics are best discussed in the context of a comprehensive evaluation.

---

🌱 Outlook

FTD is progressive, with a typical trajectory of gradual decline over 6 to 10 years from symptom onset. The pace and pattern vary depending on subtype, genetic background, and individual factors.

The identification of specific genetic mutations and pathological proteins has opened the door to targeted therapies, including antisense oligonucleotides and monoclonal antibodies directed at TDP-43 and tau. Clinical trials are underway, and the genetic forms of FTD — precisely because their molecular targets are well defined — are among the most promising frontiers in neurodegenerative disease research.

For families navigating FTD today, the most impactful steps are securing an accurate diagnosis early, connecting with clinicians who understand the disease’s unique behavioral and psychiatric dimensions, and accessing caregiver support and advanced planning resources.

---

🏥 How to Get Better

At our psychiatry practice, we have extensive experience evaluating and treating dementias and bring a thoughtful, evidence-based approach to managing them with medications and when appropriate education and psychotherapy for the patient and the family. At times, helpful adjunctive interventions can include supplements, neuromodulation, and holistic practices.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. Woolley, J. D., Khan, B. K., Murthy, N. K., Miller, B. L., & Rankin, K. P. (2011). The diagnostic challenge of psychiatric symptoms in neurodegenerative disease: rates of and risk factors for prior psychiatric diagnosis in patients with early neurodegenerative disease. Journal of Clinical Psychiatry, 72(2), 126–133.
2. Ratnavalli, E., Brayne, C., Dawson, K., & Hodges, J. R. (2002). The prevalence of frontotemporal dementia. Neurology, 58(11), 1615–1621.
3. Rascovsky, K., Hodges, J. R., Knopman, D., et al. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain, 134(9), 2456–2477.
4. Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. The Lancet, 386(10004), 1672–1682.
5. Finger, E. C. (2016). Frontotemporal dementias. CONTINUUM: Lifelong Learning in Neurology, 22(2), 464–489.
6. Tsai, R. M., & Boxer, A. L. (2016). Therapy and clinical trials in frontotemporal dementia: past, present, and future. Journal of Neurochemistry, 138(Suppl 1), 211–221.
7. Piguet, O., Hornberger, M., Mioshi, E., & Hodges, J. R. (2011). Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. The Lancet Neurology, 10(2), 162–172.
8. Seelaar, H., Rohrer, J. D., Pijnenburg, Y. A., Fox, N. C., & van Swieten, J. C. (2011). Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. Journal of Neurology, Neurosurgery & Psychiatry, 82(5), 476–486.
9. Ghosh, S., & Lippa, C. F. (2015). Clinical subtypes of frontotemporal dementia. American Journal of Alzheimer’s Disease & Other Dementias, 30(7), 653–661.
10. Mendez, M. F. (2019). Early-onset Alzheimer disease and its variants. CONTINUUM: Lifelong Learning in Neurology, 25(1), 34–51.
11. Boxer, A. L., Gold, M., Feldman, H., et al. (2020). New directions in clinical trials for frontotemporal lobar degeneration: methods and outcome measures. Alzheimer’s & Dementia, 16(1), 131–143.